Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010986 | 0.88 | MAPT (0.33) | GAAMAPT | |
| SCHEMBL8932587 | 0.82 | KDM1A (0.37) | KDM1AGAAMAPTS1PR1CYP3A4 | |
| SCHEMBL22011137 | 0.81 | OPRL1 (0.34) | GAAMAPT | |
| SCHEMBL22011232 | 0.81 | MAPT (0.32) | GAAMAPT | |
| SCHEMBL22010826 | 0.81 | GAA (0.30) | GAAMAPT | |
| SCHEMBL8932589 | 0.81 | KDM1A (0.38) | KDM1AGAAMAPTCYP3A4CYP2C8 | |
| SCHEMBL11117177 | 0.81 | SPHK1 (0.40) | GAAMAPTCYP3A4CYP2C8S1PR3 | |
| SCHEMBL11117176 | 0.81 | SPHK1 (0.40) | GAAMAPTCYP3A4CYP2C8S1PR3 | |
| SCHEMBL9320439 | 0.80 | CYP3A4 (0.35) | GAAMAPTS1PR1SGPL1S1PR4 | |
| SCHEMBL9318125 | 0.80 | CYP3A4 (0.35) | GAAMAPTS1PR1SGPL1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | KDM1A 1802/4885GAA 4418/4885MAPT 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.